OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: David Salzman

1 Projects | 1 Researchers | $349,000 Invested

2020

Gatehouse Bio, Inc.

David Salzman, PhD

Multi-class classifier for CNS Disorder type and Alzheimer’s Disease progression

  • Funding Amount: $349,000
  • Organization Type: Biotechnology/For Profit
  • Program: Biomarkers
  • Target: Other
  • Status: Closed